Navellier & Associates’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Navellier & Associates’s Portfolio JNCE Stock Details JNCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-24,611	Closed	-$206K	–	364
2021 Q4	$206K	Buy	24,611 +12,995	+112%	+$107K	0.03%	303
2021 Q3	$86K	Sell	11,616 -451	-4%	-$2.79K	0.01%	307
2021 Q2	$82K	Sell	12,067 -92	-0.8%	-$764	0.01%	296
2021 Q1	$125K	Hold	12,159	–	–	0.02%	279
2020 Q4	$85K	Sell	12,159 -657	-5%	-$5.11K	0.02%	272
2020 Q3	$105K	Buy	12,816 +160	+1%	+$992	0.02%	222
2020 Q2	$87K	Buy	+12,656	New	+$68.3K	0.02%	228

Other funds holding JNCE

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Navellier & Associates's JNCE Position: Q1 2022 in Review

Navellier & Associates sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q1 2022, closing a stake of 24,611 shares — an estimated $206K sold.

Navellier & Associates first reported a position in JNCE in Q2 2020 and held it in 7 quarters. The position peaked at $206K in Q4 2021. 113 funds tracked by Wall St. Rank hold JNCE as of Q1 2022.

Navellier & Associates reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
Navellier & Associates sold 24,611 Jounce Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $206K.
Navellier & Associates first reported a position in Jounce Therapeutics, Inc. Common Stock in Q2 2020 and held it in 7 quarters.
Navellier & Associates's Jounce Therapeutics, Inc. Common Stock position peaked at $206K in Q4 2021.
113 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Navellier & Associates's 13F filing for Q1 2022, filed 29 Apr 2022.